Last $20.80 USD
Change Today +0.21 / 1.02%
Volume 93.3K
CMRX On Other Exchanges
As of 8:10 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/14 - $27.69
52 Week Low
11/7/13 - $12.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

No Related Businessweek News Found

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

54 Employees
Last Reported Date: 05/9/14
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Lisa Ricciardi Joins Chimerix, Inc. as a Non-Executive Director

Lisa Ricciardi, non-executive director of UDG Healthcare plc was appointed as a non-executive director of Chimerix, Inc. with effect from 1 April 2014.

Chimerix, Inc. Announces the Demise of Rodman L. Drake, Director

Chimerix, Inc. announced the demise of Rodman L. Drake., Director. Mr. Drake joined the Board of Directors in 2013 and served as Chairman of the Compensation Committee.

Chimerix Inc. Announces Board Appointments

Chimerix, Inc. at its 2014 annual meeting of stockholders held on June 20, 2014, elected new directors to its board. Appointed by board of directors to fill vacancies in class II and class III of board of directors were, James M. Daly, Catherine L. Gilliss, Ph.D., R.N., FAAN, John M. Leonard, M.D., and C. Patrick Machado. C. Patrick Machado is a co-founder of Medivation, Inc. and has served on its Board of Directors since April 2014. James M. Daly currently serves as Executive Vice President and Chief Commercial Officer at Incyte Corporation a position he has held since October 2012. Catherine L. Gilliss, PhD, R.N., FAAN, currently serves as the Dean and Helene Fuld Health Trust Professor of Nursing at the Duke University School of Nursing and Vice Chancellor for Nursing Affairs at Duke University. Dr. Gilliss was appointed Dean in 2004. John M. Leonard, M.D. served as the Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie Inc. from its spin-out from Abbott Laboratories in January 2013 until retiring from those positions at the end of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $20.80 USD +0.21

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr118.00 DKK +1.50
Bioporto A/S kr2.42 DKK -0.03
Emergent Biosolutions Inc $22.61 USD +0.03
GlaxoSmithKline PLC 1,555 GBp -2.50
SIGA Technologies Inc $2.59 USD -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 163.1x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 183.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at